Federal surveillance now reports drug-resistant Candida auris in 27 states, with 3,437 clinical cases logged nationally through the week ending July 25, 2026.
The geographic spread is the newest confirmed change, and it is worth reading carefully rather than dramatically. These are provisional counts subject to revision as laboratories complete reporting, and the year-to-date pace is running about 1,000 cases below the comparable point a year earlier, when roughly 4,290 cases had been recorded, according to ABC News reporting on federal data.
For the general public, the relevant fact is who gets sick. Nearly all confirmed infections occur in people who are already seriously ill: patients on ventilators, people with central lines, feeding tubes, or urinary catheters, and residents of long-term acute care hospitals and skilled nursing facilities. If a reader has a parent in a nursing home or a relative in intensive care, this is a story about that facility's infection control practices.
The State Distribution Is Heavily Concentrated
California accounts for 873 cases, roughly a quarter of the national total. Texas follows with 433, then Tennessee with 283, Ohio with 279, Georgia with 193, Louisiana with 179, and Illinois and Arizona with 171 each. Michigan reported 146, Virginia 132, and Pennsylvania 121. The remaining states each reported fewer than 100 cases, according to Fox News reporting on CDC figures.
Concentration of this kind usually reflects two things at once: where the organism has established itself in healthcare networks, and where states screen aggressively enough to find it. A state that tests more colonized patients will report more cases than a state that does not, which means the map is partly a map of surveillance effort.
The CDC has said that cases continue to rise each year, but that the rate of increase has slowed since 2022. Total clinical cases nationally reached 6,304 in 2024, per the agency's tracking page.
Resistance Patterns Explain the Federal Concern
Candida auris is classified by the CDC as an urgent threat of antimicrobial resistance. A CDC analysis of 8,033 isolates collected in 2022 and 2023 found that more than 95 percent were resistant to fluconazole, about 15 percent to amphotericin B, and roughly 1 percent to echinocandins. Fewer than 1 percent were resistant to all three drug classes, according to the paper.
That last figure matters and is often lost. Resistance to first-line azoles is nearly universal, which is why the organism is difficult to treat. Resistance to every available option remains rare. Echinocandins remain effective in the large majority of cases.
The organism also persists on surfaces. It survives on doorknobs, bedrails, and shared equipment, and standard hospital disinfectants are not always sufficient against it. The CDC recommends private rooms for confirmed cases, gowns and gloves for all patient contact, and disinfectants specifically validated against the species.
Families with a Hospitalized Relative Have Reasonable Questions to Ask
There is no consumer product, supplement, or home cleaning routine that meaningfully affects Candida auris risk. The exposure setting is clinical, and the interventions are institutional.
Families with a relative in an intensive care unit, a long-term acute care hospital, or a skilled nursing facility can reasonably ask whether the facility screens patients transferred from other institutions, what its policy is for patients known to be colonized, and whether staff use gowns and gloves for all contact with those patients. Patient transfer between facilities is one of the main ways the organism moves through a region, and receiving facilities are not always told a patient is colonized.
Hand hygiene remains the single most useful thing a visitor can do. Visitors should clean their hands both upon entering and leaving a patient room, rather than only on the way in, and should follow the hand hygiene method specified by the facility for that unit, since precautions differ where this organism is present.
Colonization is not infection. A person can carry the organism on their skin without being sick, and most colonized patients never develop invasive disease. Those who do are typically already critically ill, making it difficult to attribute outcomes to the fungus alone.
Counts Will Shift as Laboratories Report
Reporting lags differ by laboratory capacity, and smaller states with fewer reference labs tend to post updates less frequently than large ones. Provisional surveillance data of this kind is revised, sometimes substantially, and the state totals published this month will not be the final figures for 2026. Readers should treat both the 27-state count and the 3,437-case total as current snapshots rather than settled numbers.
MedicalDaily reported earlier this month on the 23-state count and case total. The additional states and cases logged since then reflect continued reporting rather than a documented acceleration in transmission.
What remains unknown is whether the slower year-over-year pace reflects genuinely reduced transmission, changes in how aggressively states screen, or reporting lags that will close later in the year. The CDC has not attributed the difference to any single cause. The agency updates its tracking data periodically, and state health departments publish their own counts on differing schedules.
Screening practices also vary by state, shaping these numbers. Some states require facilities to screen patients transferred from high-risk settings, while others leave it to institutional discretion. Where screening is systematic, more colonized patients are identified and reported, which raises a state's count without necessarily meaning more transmission is occurring there than elsewhere.
For anyone who is not hospitalized and does not have a relative in long-term care, the appropriate response to this data is none. Healthy people in the community are not the population at risk, and these numbers do not warrant any change to the daily routine.
Key Questions Answered
What do the latest figures show? CDC provisional surveillance reports Candida auris in 27 states, with a year-to-date total of 3,437 clinical cases through the week ending July 25.
Is this an outbreak affecting the public? No. Candida auris spreads in healthcare settings and almost exclusively affects patients who are already seriously ill, particularly those with ventilators, central lines, or catheters.
Are cases rising faster than last year? No. The 2026 pace is running roughly 1,000 cases below the comparable point a year earlier, though provisional counts are revised over time.
Can it be treated? In most cases, yes. Nearly all isolates are resistant to fluconazole, but fewer than 1 percent are resistant to all three major antifungal drug classes. Echinocandins remain effective in the large majority of infections.
What should families of hospitalized patients do? Ask the facility about its screening policy for transferred patients and its precautions for colonized patients. Reinforce hand hygiene among visitors.
Does household cleaning help? Not meaningfully. The organism is a healthcare-associated pathogen, and no home product changes community risk.
When will updated numbers be released? The CDC updates its tracking data periodically. State health departments also publish counts on their own schedules, which may differ from federal figures.
